The University of Hong Kong, Hong Kong

Rina Hui is a Clinical Professor and the Director of the Centre of Cancer Medicine at the University of Hong Kong with a role to foster collaboration amongst various disciplines in cancer research and integrated teaching for medical students. She is a Medical Oncologist with a joint appointment at the Department of Medicine, School of Clinical Medicine. She has a clinical and research focus on breast and lung cancers. Rina also serves as a member of the Senate and chairs the Committee of Discontinuation at the University of Hong Kong. After completing her medical degree at The University of Sydney and specialist training at The Royal North Shore Hospital, Rina undertook translational research in cyclin D1-CDK4/6-p16INK4a-pRb pathway in breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree. Before joining HKU in January 2023, Rina was a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at the Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia. She previously served as Co-chair of Oncology Block at the Sydney Medical School, the University of Sydney and served in the written examination committee for the Royal Australasian College of Physician. She was the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Basic Sciences of Oncology Course Subject Matter Expert Group. Rina serves on the Education Committee for International Association for the Study of Lung Cancer (IASLC) and was a member of the scientific program committee for European Society of Medical Oncology Congress in 2021 and 2022. Rina has been global steering committee member and principal investigator on many clinical trials, including phase I as well as many landmark practice-changing phase III clinical studies of immunotherapy targeted therapies and antibody drug conjugates in breast and lung cancers.